Partnership brings together Revio’s drug product innovation capabilities, its AI-platform rethink Tx and OnDosis’ proprietary Dosage Manager device & associated technology platform to create IP-rich differentiated specialty products.

‍

Hyderabad, India / Gothenburg, Sweden - 18^thMar 2026:

Revio Therapeutics LLP (“Revio”) and OnDosis AB (“OnDosis”) today announced a strategic collaboration to develop a new generation of drug-device combination products designed around one of healthcare’s most persistent unmet needs: getting the right dose to the right patient, in the right way, consistently over time.

The collaboration brings together Revio’s expertise in reimagining established medicines, its proprietary AI platform (rethinkTx^™), and OnDosis’ proprietary precision dosing device platform (Dosage Manager) to identify & develop differentiated product opportunities in therapeutic areas where dosing flexibility, adherence, and ongoing patient support may be critical to achieving better real-world outcomes.

The initial focus will include selected specialty and chronic-use product categories such as narrow-therapeutic-index medicines, immunosuppressive therapies, chronic replacement treatments, and other settings where individualized dosing and treatment optimization remain important unmet needs. Revio and OnDosis are advancing initial programs in these areas, where smarter dosing, delivery, and treatment support may help improve the patient experience and unlock meaningful value for providers and healthcare systems.

“For many established medicines, the active ingredient is only part of the story,” said Sreevatsa Natarajan, Co-Founder & CEO, Revio Therapaeutics. “How the treatment is delivered, how precisely the dose can be adjusted, and how well patients can stay on therapy, all matter. Our rethinkTx^™ platform helped us identify areas where better product design can unlock that next layer of value.”

“OnDosis was built to address the limitations of one-size-fits-all dosing,” said Martin Olovsson, CEO and Co-founder. “We are confident this collaboration with Revio can help translate that vision into differentiated product opportunities across important therapeutic areas, using precision dosing and patient-centric design to support more individualized treatment. Our Dosage Manager device will play a pivotal role as a platform for these products.”

Revio’s proprietary rethinkTx^™ platform helps identify and prioritize novel product concepts across approved medicines. Here, it was used to spotlight where smarter dosing, delivery, adherence, and patient support can unlock value beyond the molecule itself.

The collaboration underscores the growing importance of integrated medicine-device solutions that can improve personalization, convenience, adherence, and treatment optimization in specialty care.

‍

About Revio Therapeutics

Revio Therapeutics is an AI-native specialty pharma company focused on reimagining proven medicines into differentiated, lower-risk product innovations. Powered by its proprietary rethink Tx^™ platform, Revio integrates product strategy, formulation thinking, and development planning to create patient-centric specialty pharmaceutical products with the potential for faster, and smarter paths to market.

‍

About OnDosis

OnDosis is a drug delivery company spun out from Astra Zeneca, focused on reimagining how oral medicines are dosed and managed through individualized treatment support. Powered by its precision dosing platform, Dosage Manager, OnDosis combines device technology and patient-centric design to help address unmet needs in personalization, adherence, and treatment optimization across multiple therapeutic areas.

‍

Media / Business Development Contact

Revio Therapeutics LLP

Sreevatsa Natarajan
Co-founder & CEO

vatsa@reviotx.com
+91-9618181612

OnDosis AB

Martin Olovsson
CEO & Co-founder

m.olovsson@ondosis.com
+46 767728501

‍

‍